Loading clinical trials...
Loading clinical trials...
An Open-Label, Dose-Escalation/Expansion Phase 1 Study of ASP4132 Given Orally to Patients With Advanced Refractory Solid Tumors and Lymphoma
Conditions
Interventions
ASP4132
Locations
5
United States
Site US10001
New Haven, Connecticut, United States
Site US10004
Chicago, Illinois, United States
Site US10002
Rochester, Minnesota, United States
Site US10003
Houston, Texas, United States
Site US10005
Fairfax, Virginia, United States
Start Date
March 23, 2015
Primary Completion Date
April 27, 2018
Completion Date
April 27, 2018
Last Updated
October 31, 2024
NCT07545603
NCT07137494
NCT05969860
NCT07218341
NCT06870760
NCT03618550
Lead Sponsor
Astellas Pharma Global Development, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions